The inhibition of other TAM-recruiting chemokines such as CCL2 and CXCR4 resulted in decreased tumor growth and progression in preclinical trials; however, their performances in combination with ICIs have not yet been evaluated (Li et al., 2017; Zhou et al., 2018). This evidence concerns the gene CXCR4 and neoplasm.